| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_06a4b4c0ff06bf9c7b97fa9b26ce5d12 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4196
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4196
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 |
| filingDate |
2018-02-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b297d618feb59bfe7806e9dadbe6ac1d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1da924b42d51e6f2eda217c7734c3802 |
| publicationDate |
2018-08-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2018243306-A1 |
| titleOfInvention |
Dual Inhibition Of CDK And HSP90 Destabilize HIF1alpha And Synergistically Induces Cancer Cell Death |
| abstract |
The present disclosure provides pharmaceutical compositions including a CDK inhibitor and an HSP90 inhibitor, as well as methods of treating cancer or a tumor in a subject by administering a CDK inhibitor and an HSP90 inhibitor to the subject. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022144042-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-109758459-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111374983-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2021380988-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-115531383-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111374983-A |
| priorityDate |
2017-02-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |